Abstract
BC15-31 is a DNA aptamer that targets heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), which plays a crucial role in the process of pre-RNA maturation and is also essential for the rapid proliferation of tumor cells. In this research, we modified BC15-31 with a phosphorothioate (PS) backbone, LNA, and 2-O-MOE to enhance its stability and target affinity. In addition, a neutral cytidinyl lipid (DNCA) and a cationic lipid (CLD) were mixed to encapsulate modified aptamers with the aim of improving their cell permeability with low toxicity. Under the DNCA/CLD package, aptamers are mainly distributed in the nucleus. A modified sequence WW-24 showed an excellent selective anti-melanoma (A375 cells, ∼25 nM, 80%) activity, targeted to both hnRNP A1 and hnRNP A2/B1 found by the BLI experiment, and induced more early and late apoptosis in vitro, which also showed stronger antitumor effect and longer accumulation time in vivo. These results provide a new strategy for further clinical applications.
Highlights
Aptamers, which Szostak and Ellington first reported in 1990, are single-stranded oligonucleotides or peptides
The only aptamer-based drug approved by the FDA occurred in 2004, which was for the treatment of neovascular age-related macular degeneration (AMD)
BC15 (74 nt) is a DNA aptamer that was found by tissue slide-based SELEX, which has a high affinity to hnRNP A1 and A2/B1 (Li et al, 2009), showing better antiproliferation activity in the HepG2 cell line (Ku et al, 2015)
Summary
Aptamers, which Szostak and Ellington first reported in 1990, are single-stranded oligonucleotides or peptides. BC15 (74 nt) is a DNA aptamer that was found by tissue slide-based SELEX, which has a high affinity to hnRNP A1 and A2/B1 (Li et al, 2009), showing better antiproliferation activity in the HepG2 cell line (Ku et al, 2015). With the mixture of DNCA and CLD as a carrier, a modified aptamer WW24 (25 nM) showed higher target affinity and serum stability, which entered the nucleus, exerting a selective anti-melanoma activity, which could target hnRNP A1 and A2/B1. It showed better antitumor effect and longer accumulation time in vivo
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
